Description

Book Synopsis
Gemcitabine was synthesised in the 1980s at Lilly Research Laboratories (Eli Lilly and Co., Indianapolis, IN). It was initially developed as an antiviral agent, but it had an extremely narrow therapeutic index due to its cytotoxicity against the parental cell lines. As it presented wide activity against various solid tumors it was then evaluated as an anticancer drug. This pyrimidine antimetabolite was firstly approved in 1996 by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer. It is currently used for the treatment of many other malignancies such as lung cancer, breast cancer, lymphoma, bladder cancer, mesothelioma and ovarian cancer. This book discusses the molecular pharmacology, and the pharmacogenetics of gemcitabine. It also discusses the antineoplastic mechanism of gemcitabine on tumour cells; the systemic adverse effects; and provides detail on the clinical uses gemcitabine has on breast cancer.

Gemcitabine: Pharmacology, Clinical Uses &

    Product form

    A Paperback / softback by Howard L Reese

    £92.79

    Includes FREE delivery

    RRP £115.99 – you save £23.20 (20%)

    Order before 4pm tomorrow for delivery by Thu 10 Sep 2026.

    1 in stock

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of Gemcitabine: Pharmacology, Clinical Uses & by Howard L Reese

      Book details

      Publisher Nova Science Publishers Inc
      Published 5 August 2014
      ISBN-13 9781633210110
      978-1633210110
      ISBN-10 1633210111
      Also in:
      Pharmacology

      Description

      Book Synopsis
      Gemcitabine was synthesised in the 1980s at Lilly Research Laboratories (Eli Lilly and Co., Indianapolis, IN). It was initially developed as an antiviral agent, but it had an extremely narrow therapeutic index due to its cytotoxicity against the parental cell lines. As it presented wide activity against various solid tumors it was then evaluated as an anticancer drug. This pyrimidine antimetabolite was firstly approved in 1996 by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer. It is currently used for the treatment of many other malignancies such as lung cancer, breast cancer, lymphoma, bladder cancer, mesothelioma and ovarian cancer. This book discusses the molecular pharmacology, and the pharmacogenetics of gemcitabine. It also discusses the antineoplastic mechanism of gemcitabine on tumour cells; the systemic adverse effects; and provides detail on the clinical uses gemcitabine has on breast cancer.

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account